Tumor specific cytotoxicity of glucosylceramide Hirosuke OkuSawitree WongtangtintharnTakayoshi Toda Original Article 26 January 2007 Pages: 767 - 775
Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib Alex HemeryckRita GeertsRoland De Coster Original Article 07 February 2007 Pages: 777 - 787
Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure–activity relationship Kazuhiro KatayamaKazuto MasuyamaYoshikazu Sugimoto Original Article 08 March 2007 Pages: 789 - 797
Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors Feng GuoStephen P. LetrentAmarnath Sharma Original Article 07 February 2007 Pages: 799 - 809
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer Wei Peng YongApurva A. DesaiMark J. Ratain Original Article 17 February 2007 Pages: 811 - 819
Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts Jonathan C. LowKishor M. WasanEmma S. Guns Original Article 10 February 2007 Pages: 821 - 829
Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent Ritu AnejaNeerupma DhimanHarish C. Joshi Original Article 07 February 2007 Pages: 831 - 839
Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro Hairong SongMarina VitaZuzana Hassan Original Article 22 February 2007 Pages: 841 - 849
Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial S. DansonM. RansonT. H. Ward Original Article 02 March 2007 Pages: 851 - 861
Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer Jong Gwang KimSang Kyun SohnWansik Yu Original Article 27 February 2007 Pages: 863 - 869
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors Muhammad Wasif SaifSandra SellersRuiwen Zhang Original Article 08 March 2007 Pages: 871 - 882
O 4-benzylfolic acid inactivates O 6-alkylguanine-DNA alkyltransferase in brain tumor cell lines Stewart P. JohnsonBarton A. KamenHenry S. Friedman Original Article 27 February 2007 Pages: 883 - 889
Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of gallium–porphyrin complex ATX-70 Nagahiko YumitaNobuo OkuyamaShin-ichiro Umemura Original Article 11 April 2007 Pages: 891 - 897
Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents Jyoti B. PatelAakanksha KhandelwalVincent C. O. Njar Original Article 08 March 2007 Pages: 899 - 905
Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model Vessela VassilevaJustin GrantMicheline Piquette-Miller Original Article 21 March 2007 Pages: 907 - 914
A pharmacokinetic study on Z-(±)-2-(1-benzylindole-3-yl-methylene)azabicyclo[2.2.2]octane-3-ol; a novel radio-sensitization agent Abeer M. Al-GhananeemZaineb F. AlbayatiPeter A. Crooks Short Communication 09 February 2007 Pages: 915 - 919
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma J. CummingsM. RansonC. Dive Short Communication 27 February 2007 Pages: 921 - 924
